Active Pharmaceutical Ingredients (APIs)

Photo
22.04.2025 • News

Suanfarma Appoints Pere Mañé as New CEO

CDMO Suanfarma appoints Pere Mañé Godina as its new CEO, marking the beginning of a new chapter for the company, focused on industrial consolidation, sustainable innovation, and global expansion.

Photo
26.11.2024 • News

IMCD Expands Pharmaceuticals Technical Centre and Wins Laura Marshall Award

IMCD Group, a global distribution partner and formulator of specialty chemicals and ingredients, recently announced the expansion of its Pharmaceuticals Technical Centre in Jakarta, Indonesia. This facility will serve as the hub for pharmaceutical development and innovation across Southeast Asia, Australia, and New Zealand.

Photo
04.09.2024 • News

Olon Acquires Huvepharma Italia

Olon continues its growth path and increases its total production capacity following the acquisition of Huvepharma Italia and its site in Garessio, Cuneo, in the northwestern part of Italy.

Photo
13.06.2024 • News

Siegfried to Acquire Early-Phase CDMO in US

Siegfried, a global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry headquartered in Zofingen, Switzerland, has signed binding agreements with Curia Global for the acquisition of an early-phase CDMO site in Grafton, Wisconsin, US.

Photo
04.06.2024 • News

Sterling Expands HPAPI Capabilities at US Facility

UK-headquartered contract development and manufacturing organization (CDMO) Sterling Pharma Solutions has invested $3 million at its US facility in Germantown, WI, to expand the company’s integrated antibody-drug conjugate (ADC) development and manufacturing capabilities.

Photo
27.05.2024 • News

Lilly Increases Investment in Indiana Site to $9 Billion

Eli Lilly plans to invest another $5.3 billion in its US manufacturing site Lebanon, Indiana, increasing the company's total investment in this site $9 billion. The investment will expand Lilly's capacity to manufacture active pharmaceutical ingredients (API) for tirzepatide injections marketed under the Zepbound and Mounjaro brands.

Photo
14.03.2024 • News

Antheia and Olon Continue Biomanufacturing Partnership

US biotech company Antheia and Olon, an Italian producer of active pharmaceutical ingredients (APIs), have announced the continuation of their ongoing partnership to utilize Olon’s fermentation infrastructure for the scale-up and commercialization of Antheia’s early products.

Photo
02.02.2024 • News

Teva Intends to Divest API Business

Israeli generics manufacturer Teva Pharmaceuticals intends to divest its active pharmaceutical ingredient (API) business, Teva API (TAPI). A standalone business unit of Teva, TAPI supplies APIs to over 1,000 customers worldwide and has approximately 4,300 employees worldwide.

Photo
29.01.2024 • News

Olon to Open New High Potency API Suite in US

Olon Group is building a state-of-the-art High Potency Active Pharmaceutical Ingredient (HPAPI) suite at its Olon USA site in Concord, Ohio. This expands the company's capabilities for handling HPAPI, with investments totaling around €40 million ($43 million) in recent years.

Photo
26.10.2023 • News

EuroAPI Announces New Governance

EuroAPI's Board of Directors decided that Karl Rotthier would step down as CEO, effective October 30, 2023. They initiated the search for a new CEO and appointed Viviane Monges, the current Board Chair, as interim CEO until a permanent successor is found, while she continues her role as Board Chair.

Photo
04.10.2023 • News

AmbioPharm Appoints Brian Gregg as CEO

Contract development and manufacturing organization (CDMO) AmbioPharm has appointed industry veteran Brian Gregg as CEO. Gregg, who has more than 30 years of experience in the peptide CDMO industry, succeeds Tim Nieters, who will be stepping down after seven years with the company.

Photo
13.06.2023 • TopicsPharma

Expanding Expertise in Highly-Potent APIs

After acquiring the two Catalonian sites in Barberà del Vallès and El Masnou about two years ago, Siegfried is now significantly expanding its expertise in the production of complex Drug Products containing Highly-Potent APIs (HPAPIs). In addition, the company has opened a new development center for oral solid dosage forms with active ingredients and HPAPIs as well as for ophthalmic sterile products. This not only strengthens Siegfried's position in the area of drug products, but also its global network and international competitiveness.

Photo
13.06.2023 • TopicsStrategy

Increasing the Sustainability of API Production

For Siegfried, sustainability is much more than a phrase with a green coating. The term, which encompasses social and economic criteria in addition to ecological aspects, is one of five central corporate values. One of the biggest levers for reducing energy and resource consumption in the pharma supply chain lies in the efficient production of active ingredients and pharmaceuticals. The company therefore works consistently on optimizing its processes.

Photo
12.06.2023 • TopicsPharma

Small Substances with Big Effects

The market for APIs is expanding significantly. Experts predict annual growth rates between 4.5 and 7.6 percent by 2029. There are plenty of good reasons for this: Chronic diseases are on the rise - and with them the need for medicines and active ingredients. In addition, the economic upswing in several emerging countries means that more people can afford novel medicines. APIs are also benefiting from the trend toward personalized medicine and the growing understanding of diseases. Meanwhile, API developers and manufacturers are working on increasingly sophisticated methods to better handle these delicate substances.

Photo
26.05.2023 • News

Olon Expands API Production

Olon, an Italian CDMO and API producer, is investing a total of €100 million in 2023 to increase production capacity, in particular at its site in Mulazzano, Lodi province.

Photo
11.05.2023 • News

Wacker Buys All of ADL BioPharma from Private Equity

German chemical group Wacker has acquired 100% of ADL Biopharma from private equity investor Kartesia for a price said to exceed €100 million. It now owns the entire 150,000 m2 production site in the northern Spanish city of Léon with fermentation capacity of just under 3,000 cbm (gross volume).

Photo
02.05.2023 • News

Glenmark Putting Chunk of API Offshoot up for Sale?

India-headquartered drugmaker Glenmark is said to be taking another look at selling a majority stake in its business with active pharmaceutical ingredients (APIs), which is wrapped up in subsidiary Glenmark Life Sciences.

Photo
21.03.2023 • NewsStrategy

Containment Solutions for HPAPI Manufacturing

Clear incentive for drug manufacturers to equip their production facilities with the capacity to process highly potent active pharmaceutical ingredients (HPAPIs). HPAPIs now account for 25% of all drugs produced globally, with some analysts projecting that it will reach a value of $40 billion by 2027.

Photo
03.03.2023 • News

US Uncovers Covid-related Bogus API-making Deals

Under US president Joe Biden, the Department of Justice has been moving energetically of late to uncover and prosecute offenses that might otherwise have been swept under heavy rugs, including Covid-related API manufacturing contracts won under unclear circumstances.

Photo
14.02.2023 • News

Veranova Completes API Expansion at Edinburgh

Macfarlan Smith, a UK-based unit of US API maker Veranova, formerly known as Johnson Matthey Health, has completed a $10 million expansion of its mid-scale active pharmaceutical ingredient (API) manufacturing capabilities in Edinburgh, Scotland.

Photo
07.12.2022 • NewsTechnology

Curiosity, Disillusionment, Persistence, Success

Given the challenges the pharmaceutical industry is facing – secure material supply, reduce operation cost and increase flexibility, enhance sustainability and safety, innovate and reduce time-to-market – the sector is poised for a breakthrough of flow chemistry.

Photo
25.11.2022 • News

Novo Nordisk Expands API Capacity

Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd.

204 more articles

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.